Last reviewed · How we verify
NCT05155592
Reduction or Discontinuation of TNF-α Inhibitor in Non-infectious Uveitis Patients
Phase 2 trial testing reduction or discontinuation of Adalimumab in Uveitis in 28 participants. Status unknown.
1 January 2023
Quick facts
| Lead sponsor | Dan Liang |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 1 January 2021 |
| Primary completion | 1 January 2023 |
| Estimated completion | 1 April 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- reduction or discontinuation of Adalimumab — full drug profile →
Conditions studied
- Uveitis — all drugs for Uveitis →
- Adalimumab — all drugs for Adalimumab →
Sponsor
Dan Liang — full company profile →
Who can join
Adults 2 to 70, any sex, with Uveitis or Adalimumab. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
TNF-α inhibitors, like Adalimumab, have good efficacy in non-infectious uveitis, but long-term use can increase the risk of drugs, and the patient's financial burden is large. The objective of this study was to explore the reduction or withdrawal of Adalimumab in uveitis patients with stable drug control, and to evaluate the efficacy and safety of drug reduction in uveitis patients, as well as the impact on their vision prognosis.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Ocular immunosuppressive microenvironment and novel drug delivery for control of uveitis.
Teabagy S, Wood E, Bilsbury E, Doherty S, et al · · 2023 · cited 15× · PMID 37172782 · DOI 10.1016/j.addr.2023.114869 -
Adalimumab Dose Reduction and Withdrawal in Stable Non-Infectious Pediatric Uveitis: An Open-Label, Prospective, Pilot Study.
Yuan PD, Hu YW, Chen XQ, Chen GY, et al · · 2025 · cited 5× · PMID 38652891 · DOI 10.1080/09273948.2024.2343084
Verify or expand the search:
- PubMed search for NCT05155592
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Uveitis
Currently open trials in the same condition.
- NCT07262437 — Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles · NA · active not recruiting
- NCT07176130 — Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore · active not recruiting
- NCT06974162 — Metagenomics for Ocular Inflammation · recruiting
- NCT06431373 — A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis · Phase 3 · active not recruiting
- NCT06310837 — Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05155592 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dan Liang
- Last refreshed: 13 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05155592.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing